Source: Annual Congress 2010 - Rare diffuse lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Arai, Y. Inoue, C. Sugimoto, A. Matsumuro, Y. Iwaki, M. Hirose, M. Kitaichi, M. Akira, S. Hayashi, K. Nakata, M. Sakatani (Sakai, Niigata, Japan). Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis. Eur Respir J 2010; 36: Suppl. 54, 750

Member's Comments

No comment yet.

Related content which might interest you: Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Serum periostin in obstructive airways disease Source: Eur Respir J 2016; 47:1383-1391 Year: 2016 Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease Source: Annual Congress 2011 - COPD: human studies Year: 2011 Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 19: 439-446 Year: 2002 Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 Association between serum YKL-40 and chronic obstructive pulmonary disease Source: International Congress 2017 – COPD biomarkers Year: 2017 Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009